Sunshine Biopharma Valuation
| SBFMW Stock | USD 0.17 0.04 19.05% |
Sunshine Biopharma seems to be overvalued based on Macroaxis valuation methodology. Our model measures the value of Sunshine Biopharma from inspecting the company fundamentals such as EBITDA of (3.82 M), operating margin of (0.13) %, and Return On Equity of -0.18 as well as reviewing its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Sunshine Biopharma's price fluctuation is out of control at this time. Calculation of the real value of Sunshine Biopharma is based on 3 months time horizon. Increasing Sunshine Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Sunshine stock is determined by what a typical buyer is willing to pay for full or partial control of Sunshine Biopharma Warrant. Since Sunshine Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Sunshine Stock. However, Sunshine Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.17 | Real 0.14 | Hype 0.17 | Naive 0.16 |
The intrinsic value of Sunshine Biopharma's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Sunshine Biopharma's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Sunshine Biopharma Warrant helps investors to forecast how Sunshine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Sunshine Biopharma more accurately as focusing exclusively on Sunshine Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Sunshine Biopharma's intrinsic value based on its ongoing forecasts of Sunshine Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Sunshine Biopharma's closest peers.
Sunshine Biopharma Cash |
|
Sunshine Valuation Trend
Analysing the historical paterns of Sunshine Biopharma's enterprise value and its market capitalization is a good way to estimate and gauge the value of Sunshine Biopharma Warrant over time and is usually enough for investors to make rational market timing decisions.
Sunshine Valuation Data Drivers
Sunshine Biopharma Total Value Analysis
Sunshine Biopharma Warrant is at this time expected to have takeover price of 0 with market capitalization of 0, debt of 657.71 K, and cash on hands of 40.56 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Sunshine Biopharma fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
0 | 0 | 657.71 K | 40.56 M |
Sunshine Biopharma Investor Information
The company recorded a loss per share of 2.21. Sunshine Biopharma had not issued any dividends in recent years. Based on the key measurements obtained from Sunshine Biopharma's financial statements, Sunshine Biopharma Warrant is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Sunshine Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Sunshine Biopharma has an asset utilization ratio of 88.1 percent. This indicates that the Company is making $0.88 for each dollar of assets. An increasing asset utilization means that Sunshine Biopharma Warrant is more efficient with each dollar of assets it utilizes for everyday operations.Sunshine Biopharma Profitability Analysis
The company reported the revenue of 24.09 M. Net Loss for the year was (4.51 M) with profit before overhead, payroll, taxes, and interest of 110.6 K.About Sunshine Biopharma Valuation
Our relative valuation model uses a comparative analysis of Sunshine Biopharma. We calculate exposure to Sunshine Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Sunshine Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 8.3 M | 8.8 M | |
| Pretax Profit Margin | (0.17) | (0.18) | |
| Operating Profit Margin | (0.20) | (0.21) | |
| Net Loss | (0.19) | (0.20) | |
| Gross Profit Margin | 0.35 | 0.36 |
Sunshine Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Sunshine Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 12.2 K |
Sunshine Biopharma Current Valuation Indicators
Valuation refers to the process of determining the present value of Sunshine Biopharma Warrant and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Sunshine we look at many different elements of the entity such as Sunshine's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Sunshine Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Sunshine Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Sunshine Biopharma's worth.Additional Tools for Sunshine Stock Analysis
When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.